Key facts
- It has raised $23.5M; the latest was Early Stage VC in Jan 2025.
- Notable investors include Sinovation Ventures, Emerging Technology Partners (Venture Capital), MindWorks Ventures, Pebble Accelerator, Pivotal BioVenture Partners (China) — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Heranova Lifesciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Heranova Lifesciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Heranova Lifesciences
Developer of medical technologies designed to offer comprehensive and innovative services for women's health problems. The company offers unmet needs in the field of obstetrics and gynecology through the integration of diagnosis, drugs, devices, data, and medical needs, enabling users and patients to get early development of innovative drugs for endometriosis and gynecological inflammation.
- Sector
- Healthcare
- HQ
- Burlington, MA, United States
- Founded
- 2022
- Website
- heranova.com/
- Ownership
- Privately Held (backing)
Heranova Lifesciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Heranova Lifesciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Heranova Lifesciences in its N-PORT filings yet. We sweep new filings monthly.